• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Treace Medical Concepts Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/8/25 4:05:29 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care
    Get the next $TMCI alert in real time by email
    8-K
    false000163062700016306272025-05-082025-05-08

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 8, 2025

    TREACE MEDICAL CONCEPTS, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

     

     

    Delaware

    001-40355

    47-1052611

    (State or other jurisdiction

    of incorporation)

    (Commission

    File Number)

    (IRS Employer

    Identification Number)

     

    100 Palmetto Park Place

    Ponte Vedra, Florida 32081

    (Address of principal executive offices, including Zip Code)

    Registrant’s telephone number, including area code: (904) 373-5940

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

     

     

     

     

    Title of each class

    Trading Symbol(s)

    Name of each exchange on which registered

    Common Stock, $0.001 par value per share

    TMCI

    The Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


     

    Item 2.02 Results of Operations and Financial Condition.

     

    On May 8, 2025, Treace Medical Concepts, Inc. (the “Company”) issued a press release regarding its financial results for the quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

     

    This information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

    Item 9.01

    Financial Statements and Exhibits.

     

    Exhibit No.

    Description

    99.1

    Press Release of Treace Medical Concepts, Inc. issued on May 8, 2025

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     


     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

     

     

     

     

     

     

    TREACE MEDICAL CONCEPTS, INC.

     

     

     

     

    Date: May 8, 2025

     

    By:

    /s/ Mark L. Hair

     

     

     

    Mark L. Hair

     

     

     

    Chief Financial Officer

     

     


    Get the next $TMCI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TMCI

    DatePrice TargetRatingAnalyst
    2/4/2025$16.00Neutral → Buy
    BTIG Research
    12/31/2024$14.50Buy
    Lake Street
    12/17/2024$8.00Neutral
    Analyst
    5/16/2024$16.00 → $6.50Buy → Neutral
    UBS
    5/8/2024$15.00 → $5.50Overweight → Equal-Weight
    Morgan Stanley
    5/8/2024$17.00 → $7.00Buy → Hold
    Truist
    5/8/2024$15.00 → $6.00Buy → Hold
    Stifel
    5/8/2024$15.00 → $8.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $TMCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Treace Medical Concepts Inc.

      SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

      11/14/24 3:38:23 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Treace Medical Concepts Inc.

      SC 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

      11/12/24 6:01:03 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Treace Medical Concepts Inc.

      SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

      11/8/24 3:44:13 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    $TMCI
    Financials

    Live finance-specific insights

    See more
    • Treace Medical Concepts Reports First Quarter 2025 Financial Results

      PONTE VEDRA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Generated revenue of $52.6 million in first quarter 2025 representing growth of 3% over the same period in 2024.Improved first quarter 2025 net loss by 15% to $(15.9) million compared to $(18.7) million in the same period in 2024. Improved adjusted EBITDA by 53% to $(3.8) million in th

      5/8/25 4:05:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace to Report First Quarter 2025 Financial Results on May 8, 2025

      PONTE VEDRA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the first quarter 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers an

      4/24/25 4:05:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

      PONTE VEDRA, Fla., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Thursday, February 27, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will rec

      2/6/25 4:15:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    $TMCI
    Leadership Updates

    Live Leadership Updates

    See more

    $TMCI
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $TMCI
    SEC Filings

    See more
    • Treace Appoints Guy Guglielmino as Chief Commercial Officer

      PONTE VEDRA, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that Guy Guglielmino joined the Company as Chief Commercial Officer. In this new position, Mr. Guglielmino will lead Treace's commercial efforts and play a pivotal role in driving the Company's next phase of rapid innovation, strategic product commercialization, and growth. "I am thrilled to welcome Guy to the Treace team," said John T. Treace, CEO, Founder and B

      12/2/24 4:15:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Medical Concepts Appoints Nathan Minnich as Senior Vice President, Marketing

      PONTE VEDRA, Fla., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced Nathan Minnich has been appointed Sr. Vice President, Marketing, effective immediately. In this new position, Mr. Minnich will lead all aspects of Treace's marketing efforts, with a focus on expanding the Company's physician outreach, patient awareness and market penetration efforts.  "I am delighted to welcome Nathan to the Treace team," said John T. Treace, CEO, Fou

      8/21/23 7:00:00 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Appoints Julie Dewey as Chief Communications and Investor Relations Officer

      PONTE VEDRA, Fla., July 12, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that Julie Dewey will join the Company as Chief Communications and Investor Relations Officer, effective July 17, 2023. In this new position, Ms. Dewey will lead all aspects of Treace's corporate communications and investor relations engagement, with a focus on expanding the company's outreach with the investment community and broadening the Company's relationships wit

      7/12/23 4:15:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Medical Concepts Reports First Quarter 2025 Financial Results

      PONTE VEDRA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Generated revenue of $52.6 million in first quarter 2025 representing growth of 3% over the same period in 2024.Improved first quarter 2025 net loss by 15% to $(15.9) million compared to $(18.7) million in the same period in 2024. Improved adjusted EBITDA by 53% to $(3.8) million in th

      5/8/25 4:05:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace to Report First Quarter 2025 Financial Results on May 8, 2025

      PONTE VEDRA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the first quarter 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers an

      4/24/25 4:05:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Announces Upcoming Board Chair Transition

      PONTE VEDRA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that its Board of Directors has appointed John. T. Treace, Chief Executive Officer and Founder of Treace, as the Chairman of the Board to be effective immediately following the 2025 annual meeting of stockholders. Mr. John. T. Treace will succeed James T. Treace, who notified the Board that he will retire from the Board when his current term as a director ends at

      4/7/25 8:00:00 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 filed by Treace Medical Concepts Inc.

      S-8 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

      5/9/25 8:43:56 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Treace Medical Concepts Inc.

      10-Q - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

      5/8/25 4:10:24 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Medical Concepts Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

      5/8/25 4:05:29 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    $TMCI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Treace John T. bought $524,064 worth of shares (60,000 units at $8.73), increasing direct ownership by 0.89% to 6,796,190 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      3/4/25 6:30:03 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Treace John T. bought $265,630 worth of shares (50,000 units at $5.31), increasing direct ownership by 0.77% to 6,523,095 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      9/17/24 5:17:19 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Director Treace James T bought $501,035 worth of shares (84,000 units at $5.96), increasing direct ownership by 7% to 1,223,441 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      8/19/24 9:00:08 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    $TMCI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Treace Medical Concepts upgraded by BTIG Research with a new price target

      BTIG Research upgraded Treace Medical Concepts from Neutral to Buy and set a new price target of $16.00

      2/4/25 7:10:07 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Treace Medical Concepts with a new price target

      Lake Street initiated coverage of Treace Medical Concepts with a rating of Buy and set a new price target of $14.50

      12/31/24 7:48:21 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Analyst resumed coverage on Treace Medical Concepts with a new price target

      Analyst resumed coverage of Treace Medical Concepts with a rating of Neutral and set a new price target of $8.00

      12/17/24 8:22:27 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    $TMCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Innovation Officer Scanlan Sean F. exercised 50,000 shares at a strike of $1.05 and sold $398,460 worth of shares (50,000 units at $7.97) (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      3/19/25 9:30:04 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • SVP, Sales Berutti Aaron covered exercise/tax liability with 2,543 shares, decreasing direct ownership by 1% to 209,999 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      3/11/25 9:00:14 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Treace John T. covered exercise/tax liability with 7,084 shares, decreasing direct ownership by 0.10% to 6,789,106 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      3/11/25 9:00:13 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care